Everest Medicines gets China NMPA approval for CARDAMYST® in PSVT
Everest Medicines announced China’s NMPA approval of CARDAMYST® for converting acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.
SHANGHAI, Sept.
3, 2026 // -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that China's National Medical Products…